Discover and read the best of Twitter Threads about #ISNWCN
Most recents (11)
1) Welcome to a new #accredited #tweetorial from our good friends and #diabetes experts @GoggleDocs, specifically @drkevinfernando, @drpatrickholmes, & @AmarPut. They have put their 🗣️s together to provide us with a summary of the first-ever consensus statement from ...
2) ... @AmDiabetesAssn & @goKDIGO, which were discussed at the recently concluded #isnwcn congress in Kuala Lumpur. This joint document nicely summarizes important recent advances and practice-changing data for the management of diabetic #kidneydisease #DKD. 
3) This program is #accredited for CE/#CME #physicians #physicianassociates #nurses #pharmacists #nursepractitioners & is supported by an independent educational grant from the Boehringer Ingelheim/Lilly Alliance. It is not intended for US based healthcare professionals.
Advancing Evidence-Based Care in Diabetes and CKD
#ISNWCN 🇲🇾 #Nephpearls
👉 kdigo.org/wp-content/upl…
#ISNWCN 🇲🇾 #Nephpearls
👉 kdigo.org/wp-content/upl…
Glucose-lowering agents in Type 2 Diabetes (T2D) and CKD: Indications and dose adjustments
#ISNWCN 🇲🇾 #Nephpearls
#ISNWCN 🇲🇾 #Nephpearls
.@goKDIGO Glomerular Diseases Guideline: Reflections on a Decade of Progress with @adrianliew8 @ReichHeather @Dr_KeishaGibson
#ISNWCN 🇲🇾 #Nephpearls
👉 kdigo.org/wp-content/upl…
#ISNWCN 🇲🇾 #Nephpearls
👉 kdigo.org/wp-content/upl…
IgA Nephropathy: A 1st step is in treating IgA Nephropathy is assessing "prognosis" based on data available at the time of biopsy
@goKDIGO suggest using the "prediction tool" that was derived from the largest & most geographically diverse cohort to date
#ISNWCN 🇲🇾 #Nephpearls
@goKDIGO suggest using the "prediction tool" that was derived from the largest & most geographically diverse cohort to date
#ISNWCN 🇲🇾 #Nephpearls
IgA Nephropathy: The @goKDIGO treatment algorithm recommends consideration of use of corticosteroids in patients with "persistent proteinuria >1g/day" if the risk/benefit profile is favorable
📌 A GFR of 30 is considered a threshold for treatment
#ISNWCN 🇲🇾 #Nephpearls
📌 A GFR of 30 is considered a threshold for treatment
#ISNWCN 🇲🇾 #Nephpearls
#ISNWCN Management of tubular disorders in collaboration with @IPNA_PedNeph
1️⃣ Bartter Syndrome, better to say Bartter like syndromes and don’t forget new forms of Gitelman syndrome. Go for genetic study I possible. Some forms carry the risk of CKD
1️⃣ Bartter Syndrome, better to say Bartter like syndromes and don’t forget new forms of Gitelman syndrome. Go for genetic study I possible. Some forms carry the risk of CKD
#ISNWCN @ISNWCN @ISNkidneycare Theme Symposium: New Kids on the Block to Treat #DKD and #CKD.
@Heerspink79 : GLP1 agonists and SGLT2i in limiting DKD progression.
SGLT2 inhibitors reduce progression of CKD. Degree of albuminuria reduction - determinant of benefit.
1/4
@Heerspink79 : GLP1 agonists and SGLT2i in limiting DKD progression.
SGLT2 inhibitors reduce progression of CKD. Degree of albuminuria reduction - determinant of benefit.
1/4
#ISNWCN New Rx #DKD and #CKD @Heerspink79
Do GLP1 agonists help retard DKD progression?
- Semaglutide ⬇️ UACR in DKD
- Exenatide⬇️ eGFR decline more in those with higher proteinuria
- Dulaglutide ⬇️ CKD progression in DKD
- FLOW: study of semaglutide in DKD recruiting
2/4
Do GLP1 agonists help retard DKD progression?
- Semaglutide ⬇️ UACR in DKD
- Exenatide⬇️ eGFR decline more in those with higher proteinuria
- Dulaglutide ⬇️ CKD progression in DKD
- FLOW: study of semaglutide in DKD recruiting
2/4
#ISNWCN New Rx #DKD and #CKD @Heerspink79 Should we use SGLT2i + GLP1antagonists together?
- Combination reduces albuminuria more than either alone
*Novel GLP1 + glucagon agonist*
- Significantly reduced HbA1c, body weight and CV outcomes.
Large RCT - initiated soon
3/4
- Combination reduces albuminuria more than either alone
*Novel GLP1 + glucagon agonist*
- Significantly reduced HbA1c, body weight and CV outcomes.
Large RCT - initiated soon
3/4
Updates on IgA treatment by Prof
Wong Muh Geot @drmuhgeot
Testing trial with reduced dose of methylpred.
#ISNWCN
@ISNWCN
@ISNkidneycare
Wong Muh Geot @drmuhgeot
Testing trial with reduced dose of methylpred.
#ISNWCN
@ISNWCN
@ISNkidneycare
Testing trial was terminated earlier due to the adverse side effects. However, there is a lower risk of infection with reduced dose of MTP in Testing 2.
#ISNWCN
@ISNWCN
@ISNkidneycare
#ISNWCN
@ISNWCN
@ISNkidneycare
Reduced dose MTP is shown to reduce the risk of kidney failure, but we have to choose our patients carefully to weigh the benefits against side effects.
#ISNWCN
@ISNWCN
@ISNkidneycare
#ISNWCN
@ISNWCN
@ISNkidneycare
An inconvenient truth: 2–7 million people with kidney failure worldwide die prematurely because they do not have access to kidney replacement therapy (dialysis/transplantation) #ISNWCN @WHO
#Kidney #disease is the third fastest-growing cause of death, projected from the current 16th position to 5th in less than 20 years
There are huge inequities in access to kidney replacement therapy worldwide, with 94% patients being in high and upper-middle income countries
The progressive increase in the risk of pre-term delivery with CKD at #ISNWCN - describes
@gb_piccoli
@gb_piccoli
Action items #ISNWCN
Pathophysiological role of endothelin in CKD ca. 2014 from @Kidney_Int
#ISNWCN 🇦🇺🦘#Nephpearls
👉🏼 kidney-international.org/article/S0085-…
#ISNWCN 🇦🇺🦘#Nephpearls
👉🏼 kidney-international.org/article/S0085-…
SONAR: Atrasentan & renal events in patients w/ type 2 diabetes and CKD: a double-blind, randomised, placebo-controlled trial ca. 2019 from @TheLancet
#ISNWCN 🇦🇺🦘 #Nephpearls
👉🏼 thelancet.com/journals/lance…
#ISNWCN 🇦🇺🦘 #Nephpearls
👉🏼 thelancet.com/journals/lance…
SONAR: Atrasentan & renal events in patients w/ type 2 diabetes and CKD: a double-blind, randomised, placebo-controlled trial ca. 2019 from @TheLancet #Nephpearls
👉🏼 thelancet.com/journals/lance…
👉🏼 thelancet.com/journals/lance…
SGLT2 Inhibitors and Cardiorenal Outcomes in the February 2019 issue of @KidneyNews
#ISNWCN 🇦🇺🦘 #Nephpearls
👉🏼 kidneynews.org/kidney-news/is…
#ISNWCN 🇦🇺🦘 #Nephpearls
👉🏼 kidneynews.org/kidney-news/is…
EMPA-REG: Empagliflozin, CV outcomes and mortality in Type 2 Diabetes ca. 2015 from @NEJM
#VisualAbstract by @kidney_boy
#ISNWCN 🇦🇺🦘 #Nephpearls
👉🏼 nejm.org/doi/pdf/10.105…
#VisualAbstract by @kidney_boy
#ISNWCN 🇦🇺🦘 #Nephpearls
👉🏼 nejm.org/doi/pdf/10.105…
CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM
#VisualAbstract by @kidney_boy
#ISNWCN 🇦🇺🦘 #Nephpearls
👉🏼 nejm.org/doi/pdf/10.105…
#VisualAbstract by @kidney_boy
#ISNWCN 🇦🇺🦘 #Nephpearls
👉🏼 nejm.org/doi/pdf/10.105…
2. Changing landscapes in PR-AKI
Rising incidence in developed countries - mainly because it increasing maternal age and comorbidities #ISNWCN
Rising incidence in developed countries - mainly because it increasing maternal age and comorbidities #ISNWCN
